Library

An economic evaluation of varicella vaccination in Italian adolescents / Nancy Thiry in Vaccine, 22(2004)27-28 ([09/09/2004])  

[article] An economic evaluation of varicella vaccination in Italian adolescents [printed text] / Nancy Thiry, Author ; Philippe Beutels, Author ; Francesco Tancredi, Author ; A. Zanetti, Author ; Paolo Bonanni, Author ; Giovanni Gabutti, Author ; Pierre Van Damme, Author . - 2004 . - 3546-3562. Languages : English (eng) in Vaccine > 22(2004)27-28 [09/09/2004] . - 3546-3562 Descriptors: Classification W 1 Serials. Periodicals Indexation Adolescent ; Adult ; Age Factors ; Aged ; Chickenpox Vaccine ; Child ; Child, Preschool ; Cost of Illness ; Cost-Benefit Analysis ; Economics ; Encephalitis, Varicella Zoster ; Epidemiology ; Female ; Hospitalization ; Humans ; Italy ; Journal Article ; Male ; Markov Chains ; Mass Immunization ; Middle Aged ; Netherlands ; Peer Review ; prevention and control ; statistics and numerical data [Subheading] Abstract: An economic evaluation was performed to assess five varicella vaccination scenarios targeted to 11-year-old Italian adolescents. The scenarios were: "compulsory vaccination" of all adolescents, recommended vaccination of susceptible adolescents on the basis of an "anamnestic screening", a "blood test" or a combination of both ("both tests") and vaccination of adolescents in the private sector, at the parents' charge ("private vaccination"). Probabilities and unit costs were taken from published sources and experts opinion. The accuracy of the anamnestic screening (81.6% sensitivity and 87.3% specificity) was derived from a separate descriptive study among 344 Italian adolescents. The costs and benefits of each scenario were simulated using a Markov model and cost-effectiveness, budget-impact and cost-benefit analyses were conducted. Of all considered scenarios, "both tests" and "anamnestic screening" were the most appealing options with an estimated net direct cost of 5058 and 8929 per life-year gained (compared to no vaccination) versus 14,693-42,842 for the other scenarios. These two scenarios further resulted in substantial net savings for society (over 600,000 per cohort, BCR: 2.17). The need for a serological confirmation was highly dependent on the sensitivity of the anamnestic screening, which is believed to increase once such a program is launched. For practical considerations, "anamnestic screening" seems to be the most convenient option. Link for e-copy: http://tiny.cc/xktyn Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1773 [article]

Convincing or confusing? / Philippe Beutels in Vaccine, 25(2007)8 ([02/09/2007])  

[article] Convincing or confusing? : Economic evaluations of childhood pneumococcal conjugate vaccination [printed text] / Philippe Beutels, Author ; Nancy Thiry, Author ; Pierre Van Damme, Author . - 2007 . - 1355-1367. Research Support, Non-U.S. Gov't Review Languages : English (eng) in Vaccine > 25(2007)8 [02/09/2007] . - 1355-1367 Descriptors: Classification W 1 Serials. Periodicals Indexation Child, Preschool ; Economics ; Humans ; immunology ; Infant ; Journal Article ; Netherlands ; Peer Review ; Pneumococcal Infections ; Pneumococcal Vaccines ; prevention and control ; Vaccines Conjugate Abstract: We review 15 economic analyses of pneumococcal conjugate vaccines, published between 2002 and 2006, in terms of methodology, assumptions, results and conclusions. We found a great diversity in assumptions (eg, vaccine efficacy parameters, incidence rates for both invasive and non-invasive disease) mainly due to local variation in data and opinions. Accordingly, the results varied greatly, from total net savings to over euro 100,000 per discounted QALY gained. The cost of the vaccination program (determined by price per dose and schedule (4 or 3 doses, or fewer)), and likely herd immunity impacts are highly influential though rarely explored in these published studies. If the net long-term impact (determined by a mixture of effects related to herd immunity, serotype replacement, antibiotic resistance and cross reactivity) remains beneficial and if a 3-dose schedule confers near-equivalent protection to a 4-dose schedule, the cost-effectiveness of PCV7 vaccination programs can be viewed as attractive in developed countries. Link for e-copy: http://tiny.cc/aalwe Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1767 [article]

Cost-effectiveness analysis of rotavirus vaccination of Belgian infants / J Bilcke / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2007)  

Cost-effectiveness analysis of rotavirus vaccination of Belgian infants [printed text] / J Bilcke, Author ; Philippe Beutels, Author ; F De Smet, Author ; Germaine Hanquet, Author ; M. Van Ranst, Author ; Pierre Van Damme, Author . - Brussels (Doorbuilding (10th), Bld Jardin Botanique, 55, 1000, Belgium) : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2007 . - vi, 143 p, 3 ann. : ill. ; 30 cm.. - (KCE Reports. Health Technology Assessment (HTA); 54C) . 0 € Study nr 2007-09 Languages : English (eng) Descriptors: Indexation 2007-09 ; Cost-effectiveness analysis ; R54 ; Rotavirus Vaccines Classification WC 501 RNA virus infections (General or not elsewhere classified) Link for e-copy: https://kce.fgov.be/sites/default/files/page_documents/d20071027311.pdf Format of e-copy: .PDF (2,2 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1641

Copies

Barcode	Call number	Media type	Location	Section	Status
No copy

Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)  

Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood [printed text] / Philippe Beutels, Author ; Adriaan Blommaert, Author ; Germaine Hanquet, Author ; J Bilcke, Author ; Nancy Thiry, Author ; Martine Sabbe, Author ; J. Verhaegen, Author ; F De Smet, Author ; Michael Callens, Author ; Pierre Van Damme, Author . - Brussels (Doorbuilding (10th), Bld Jardin Botanique, 55, 1000, Belgium) : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011 . - VIII, 101 p. : ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 155C) . ISSN : D/2011/10.273/21 : € 0,00 Study 2009-52 (HTA): Incremental cost-effectiveness of the 7, 10 and 13-valent pneumococcal conjugate vaccines Languages : English (eng) Descriptors: Classification WC 217 Pneumococcal infections Indexation 2009-52 ; Cost-Benefit Analysis ; Infant ; Pneumococcal Infections ; Pneumococcal Vaccines ; R155 ; Vaccines Conjugate Contents note: LIST OF TABLES 3-- LIST OF FIGURES 5-- GLOSSARY 6-- 1 BACKGROUND 7-- 1.1 THE SEVEN-VALENT CONJUGATE PNEUMOCOCCAL VACCINE 7-- 1.2 TWO NEW CONJUGATE PNEUMOCOCCAL VACCINES 8-- 2 OBJECTIVES AND RESEARCH QUESTIONS 9-- 3 LITERATURE SEARCHES AND METHODS 10-- 4 IMMUNOGENICITY, EFFICACY AND EFFECTIVENESS OF CURRENT-- PNEUMOCOCCAL CONJUGATE VACCINES 13-- 4.1 SEVEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV7) 13-- 4.1.1 Clinical trials – efficacy of PCV7 13-- 4.1.2 Post-licensure studies – effectiveness of PCV7 14-- 4.1.3 Pathogenicity of serotypes 21-- 4.2 TEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV10) 22-- 4.2.1 Clinical trials – immunogenicity of PCV10 22-- 4.2.2 Clinical trials – efficacy of PCV10 24-- 4.3 THIRTEEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) 25-- 4.3.1 Clinical trials – immunogenicity of PCV13 25-- 5 DISEASE BURDEN IN BELGIUM 27-- 5.1 INVASIVE PNEUMOCOCCAL DISEASE (IPD) 28-- 5.2 ACUTE OTITIS MEDIA (AOM) AND COMMUNITY ACQUIRED PNEUMONIAE (CAP) 35-- 5.3 HOSPITALISATIONS 36-- 5.3.1 Meningitis hospitalisations 36-- 5.3.2 Bacteremia and septicaemia hospitalisations 38-- 5.3.3 Pneumonia hospitalisations 39-- 5.4 DEATHS 39-- 5.4.1 Invasive pneumococcal diseases (IPD) deaths 39-- 5.4.2 (Pneumococcal) pneumonia deaths 40-- 5.4.3 Pneumococcal meningitis deaths 40-- 5.4.4 Pneumococcal septicaemia deaths 41-- 6 ECONOMIC EVALUATIONS OF PCV10 AND PCV13 42-- 6.1 MODELS STRUCTURE 42-- 6.2 MAIN ASSUMPTIONS AND RESULTS 43-- 7 MATHEMATICAL MODELS OF PNEUMOCOCCAL TRANSMISSION 46-- 8 COST-UTILITY ANALYSIS OF PCV10 AND PCV13 IN BELGIUM 48-- 8.1 STUDY DESIGN 48-- 8.1.1 General 48-- 8.1.2 Vaccination options 48-- 8.1.3 Mathematical model structure 49-- 8.2 MODEL INPUT DATA 50-- 8.2.1 Epidemiological parameters and transition probabilities 50-- 8.2.2 Vaccine efficacy estimates 52-- 8.2.3 Direct costs 61-- 8.2.4 Health-Related Quality of Life 63-- 8.3 RESULTS 64-- 8.3.1 Cost-effectiveness acceptability curves 64-- 8.3.2 Incremental costs, outcomes and cost-effectiveness ratios 68-- 8.3.3 Further scenario analyses 77-- 8.3.4 Influence of vaccine price and of inclusion or exclusion of AOM 77-- 8.3.5 Influence of serotype replacement and herd immunity assumptions 79-- 8.3.6 Joint influence of vaccine price, expected serotype replacement and of the additional-- effectiveness of PCV10 versus PCV13 against otitis media 79-- 8.3.7 Budget impact analysis 82-- 9 CONCLUSION 83-- 10 APPENDICES: ADDITIONAL COST-EFFECTIVENESS ACCEPTABILITY-- CURVES 86-- 11 REFERENCES 88 Link for e-copy: https://kce.fgov.be/sites/default/files/page_documents/kce_155c_pneumococcal_vac [...] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2572

Copies

Barcode	Call number	Media type	Location	Section	Status
No copy

Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium / Adriaan Blommaert in Vaccine, 32(2014)46 ([10/21/2014])  

[article] Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium [printed text] / Adriaan Blommaert, Author ; J Bilcke, Author ; Yannick Vandendijck, Author ; Germaine Hanquet, Author ; Niel Hens, Author ; Philippe Beutels, Author . - 2014 . - 6075-6083. Languages : English (eng) in Vaccine > 32(2014)46 [10/21/2014] . - 6075-6083 Descriptors: Classification W 1 Serials. Periodicals Indexation 2010-02-2 ; Belgium ; Health Personnel ; Influenza Vaccines ; Journal Article ; Models, Econometric ; Peer Review ; R204 ; Risk Abstract: Risk groups with increased vulnerability for influenza complications such as pregnant women, persons with underlying illnesses as well as persons who come into contact with them, such as health care workers, are currently given priority (along with other classic target groups) to receive seasonal influenza vaccination in Belgium. We aimed to evaluate this policy from a health care payer perspective by cost-effectiveness analysis in the three specific target groups above, while accounting for effects beyond the target group. Increasing the coverage of influenza vaccination is likely to be cost-effective for pregnant women (median euro6589 per quality-adjusted life-year (QALY) gained [euro4073-euro10,249]) and health care workers (median euro24,096/QALY gained [euro16,442-euro36,342]), if this can be achieved without incurring additional administration costs. Assuming an additional physician's consult is charged to administer each additional vaccine dose, the cost-effectiveness of vaccinating pregnant women depends strongly on the extent of its impact on the neonate's health. For health care workers, the assumed number of preventable secondary infections has a strong influence on the cost-effectiveness. Vaccinating people with underlying illnesses is likely highly cost-effective above 50 years of age and borderline cost-effective for younger persons, depending on relative life expectancy and vaccine efficacy in this risk group compared to the general population. The case-fatality ratios of the target group, of the secondary affected groups and vaccine efficacy are key sources of uncertainty. Link for e-copy: http://dx.doi.org/10.1016/j.vaccine.2014.08.085 Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3701 [article]

Economic evaluation of vaccination programmes in human / Philippe Beutels / Antwerpen [Belgium] : Universiteit Antwerpen (UA) (2002)

Permalink

Economic evaluations of pneumococcal vaccination strategies in adults / Nancy Thiry in Acta Clinica Belgica, 60(2005)6 ([11/02/2005])  

Permalink

Economic evaluations of varicella vaccination programmes / Nancy Thiry in Pharmacoeconomics, 21(2003)1 ([01/01/2003])  

Permalink

Effecten en kosten van de vaccinatie van Belgische kinderen met geconjugeerd pneumococcenvaccin / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2006)  

Permalink

Effects and costs of pneumococcal conjugate vaccination of Belgian children / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2006)  

Permalink

Effets et coûts de la vaccination des enfants belges au moyen du vaccin conjugué antipneumococcique / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2006)  

Permalink

Estimating dynamic transmission model parameters for seasonal influenza by fitting to age and season-specific influenza-like illness incidence / Nele Goeyvaerts in Epidemics, 13(2015)Decembre ([12/01/2015])    

Permalink

Evaluatie van universele en doelgroep hepatitis A vaccinatie opties in België / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)  

Permalink

Évaluation de programmes de vaccination généraux et ciblés contre l’hépatite A en Belgique / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)  

Permalink

Kosten-effectiviteitsanalyse van rotavirus vaccinatie van zuigelingen in België / J Bilcke / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2007)  

Permalink